Clinical Trial Update: Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure [Phase 4]

View source ↗

Summary

This is a Phase 4 clinical trial comparing acalabrutinib monotherapy to investigator's choice of treatment in patients with chronic lymphocytic leukemia and hea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Heart Failure

Drugs mentioned

• Acalabrutinib (acalabrutinib)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Lymphocytic Leukaemia, Heart Failure | Phase 4 | Status: RECRUITING